Fujifilm (OTCMKTS:FUJIY) Shares Gap Down - Here's What Happened

Key Points

• Fujifilm's shares experienced a gap down before the market opened on Monday, starting at $11.35 after previously closing at $11.81.
• The stock was dropped from a "buy" to a "hold" rating by Wall Street Zen as of May 23rd.
• The company's recent earnings report revealed an EPS of $0.15, meeting analyst expectations, with total revenue of $5.08 billion for the quarter.

Fujifilm Holdings Corp. (OTCMKTS:FUJIY - Get Free Report)'s stock price gapped down prior to trading on Monday . The stock had previously closed at $11.81, but opened at $11.35. Fujifilm shares last traded at $11.81, with a volume of 1,672 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen downgraded Fujifilm from a "buy" rating to a "hold" rating in a report on Friday, May 23rd.

Fujifilm Price Performance

The firm has a fifty day simple moving average of $10.73 and a 200 day simple moving average of $10.46. The company has a market capitalization of $30.25 billion, a PE ratio of 10.95, a P/E/G ratio of 3.64 and a beta of 0.67. The company has a debt-to-equity ratio of 0.14, a quick ratio of 0.92 and a current ratio of 1.40.

Fujifilm (OTCMKTS:FUJIY - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The technology company reported $0.15 earnings per share for the quarter, hitting analysts' consensus estimates of $0.15. The firm had revenue of $5.08 billion during the quarter, compared to analysts' expectations of $760.41 billion. Fujifilm had a return on equity of 7.73% and a net margin of 7.93%. Equities analysts anticipate that Fujifilm Holdings Corp. will post 0.66 EPS for the current year.

About Fujifilm

FUJIFILM Holdings Corporation develops, manufactures, sells, and services imaging, healthcare, materials, and business innovation solutions worldwide. The company's Healthcare segment provides products and services, such as medical devices, biomedical contract development and manufacturing organization, pharmaceutical, regenerative medicine, and cosmetics and supplements in the areas of prevention, diagnosis, and treatment.